Navigation Links
New Study Shows the Use of MEDIHONEY(TM) Wound & Burn Dressing is Associated With Reduction in Wound Size
Date:4/8/2008

International Wound Journal article cites pH modulation as a key method of

action

PRINCETON, N.J., April 8, 2008 /PRNewswire-FirstCall/ -- Derma Sciences Inc (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced today that the most recent study involving MEDIHONEY(TM) Wound & Burn Dressing shows that use of the dressings are associated with a reduction in wound size, possibly driven in part by a significant reduction in overall wound pH. The 20-patient study will be published in the May edition of the International Wound Journal. The article -- "The impact of Manuka honey dressings on the surface pH of chronic wounds" -- was written by Georgina T. Gethin, Seamus Cowman and Ronan Conroy, all of the Royal College of Surgeons, Dublin, Ireland. The May edition of the International Wound Journal is a special edition of this globally-recognized peer-reviewed journal, and will be distributed to the attendees of the upcoming World Union of Wound Healing Societies conference, to be held in Toronto this June 4-8.

According to the abstract for the article, the authors evaluated the progression of 20 non-healing ulcers of various etiologies following application of the dressings over a period of two weeks. The dressings were provided by Derma Sciences' global commercialization partner, Comvita New Zealand, Inc. The authors cite their rationale for researching pH modulation in chronic wounds as follows:

"Chronic non-healing wounds have an elevated alkaline environment. The acidic pH of Manuka honey makes it a potential treatment for lowering wound pH, but the duration of the effect is unknown. Lowering wound pH can potentially reduce protease activity, increase fibroblast activity and increase oxygen release, consequently aiding wound healing."

After two weeks of treatment with the dressings, the authors concluded that, for this group of previously non-healing ulcers, "the use of Manuka honey dressings was associated with a statistically significant decrease in wound pH and a reduction in wound size." Significant wound progression during a two-week period is noted as a strong predictor of good wound healing outcomes.

Commenting on the article, Derma Sciences CEO Edward Quilty said, "Method of action is obviously an important component to having a better understanding of a medical device. Based on the results clinicians have seen all over the world, and recently here since our launch in the US and Canada, we have known for quite some time that the dressings work. Now we are getting a better understanding as to 'why'. Providing the answer to this question will no doubt increase product usage, as it makes clinicians feel more comfortable that the product has been studied thoroughly, it is effective, and we understand why it is effective. Although pH modulation and the product's high osmolarity have long been thought to contribute to the effectiveness of the product, it is rewarding to see these beliefs are being confirmed through good, well structured trials."

He also added, "This is yet another important study focused on non-healing or recalcitrant wounds that are not progressing with other advanced wound care modalities. It will only help to improve MEDIHONEY(TM)'s growing reputation as an effective dressing to 'kick-start' the healing process. This is what clinicians are reporting to us after their lengthy clinical evaluations. As we planned, we believe clinicians are gaining significant confidence in our dressing for very troublesome wounds. Once this is established in the market, it then becomes only a matter of time before the dressing is more commonly used even from the onset of a wound. This will be reflected in growing product sales as we ramp up throughout 2008 and into 2009."

About Derma Sciences

Derma Sciences is a manufacturer and marketer of advanced wound-care products, with operations based in the US and Canada, and sales worldwide. The company recently launched its MEDIHONEY(TM) Wound & Burn dressings with Active Leptospermum Honey. The Company has also obtained FDA clearance to market and sell its MOBILITY1(TM) boot and compressor device for the treatment of venous ulcers, lymphedema, and other conditions that require compression therapy. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com.

About the International Wound Journal

International Wound Journal (IWJ) is a multi-disciplinary forum providing the best quality information, research data and education on all aspects of wounds and wound healing in the fields of surgery, dermatology, oncology, nursing, radiotherapy, physiotherapy, and podiatry. Peer-reviewed, the Journal is the primary information resource for all healthcare professionals caring for patients with wound infections, the diabetic foot, leg ulcers and chronic wounds. The Editorial Team represents the full spectrum of health professionals involved in the care of patients with wounds, ensuring only the most current and comprehensive research impacting on patient care is published. Reflecting the international nature of the Journal, all key abstracts are translated into French, German, Italian, Spanish and Swedish. IWJ is indexed by MEDLINE and CINAHL. Information on the journal can be found at http://www.blackwellpublishing.com/journal.asp?ref=1742-4801&site=1.

Forward-looking Statements

Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements Include but are not limited to, those discussed in the Company's filings with the Securities and Exchange Commission.

Contact: Derma Sciences Inc Allen & Caron Inc

Edward J. Quilty Rudy Barrio (US Investors)

Chairman and CEO r.barrio@allencaron.com

equilty@dermasciences.com Brian Kennedy (media)

(609) 514-4744 brian@allencaron.com

(212) 691-8087


'/>"/>
SOURCE Derma Sciences Inc
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Study Shows the Personal Touch Is Key to Maintaining Weight Loss
2. Medical errors cost US $8.8B, result in 238,337 potentially preventable deaths: HealthGrades study
3. ASCRS to participate in and co-fund study on post-lasik quality of life with US FDA
4. New study finds adverse effects of estrogen replacement therapy are related to the dose
5. Geisinger study: Use of digital health records improve health of the elderly
6. Occupational therapists use Wii for Parkinsons study
7. Preliminary Data From Pitt County Memorial Hospital Study Show Benefit of Active Surveillance on Reducing MRSA VAP Rates in Surgical ICU
8. Animal Study Links Social Standing With Drug Use Risk
9. Study Shows Anger Has Its Uses
10. 1st US study -- gymnastics lands thousands in ER
11. Study finds economic burden of health insurance increasing for small employers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Milwaukee, WI (PRWEB) , ... March 29, 2017 , ... ... as its exclusive provider of co-op eligible dealer websites for its network of more ... line of professional landscaping and agricultural equipment including rotary and flail mowers and cutters, ...
(Date:3/29/2017)... ... March 29, 2017 , ... Full Contact K9, an ... Pet Protect Law that assists dog owners in creating legally-enforceable pet trusts ... in taking the natural next step to protect their new companion. Says Evan Dunbar, ...
(Date:3/29/2017)... , ... March 30, 2017 , ... Youth Futures International ... success and feedback from high school and college students who have participated in the ... July 7-23 and YFI is now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org ...
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy Network, a ... at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. , Ben ... the visionary leader in the training of physicians, scientists, and members of the ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... insight into the challenges employers face in trying to balance both short-term and ... benefits programs? Adding to the growing complexity, companies are finding that the ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017  Designers of primary cell wearable medical and ... 50% and extend battery life with the MAX20310 ultra-low ... (PMIC) from Maxim Integrated Products, Inc. (NASDAQ: ... voltage of just 0.7V for new high-energy density battery ... well as the more common Alkaline battery architecture. With ...
(Date:3/29/2017)... 29, 2017   Dynatronics Corporation (NASDAQ: ... of Cynthia L. McHenry (Cyndi) as ... for leading Dynatronics manufacturing, distribution, and purchasing operations ... Dynatronics, CEO Kelvyn H. Cullimore, Jr. ... search process conducted by the company as it ...
(Date:3/29/2017)... AVIV, Israel , March 29, 2017 ... agreement in which Exeltis will obtain exclusive marketing rights for Neurim,s ... ... an age-appropriate drug targeted to treat sleep disorders in children with ... be the first sleep medication approved for children. The ...
Breaking Medicine Technology: